These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 24717970)

  • 1. Evaluation of anticoagulants for serologic assays of cholera vaccination.
    Yang JS; Kang SS; Yun CH; Han SH
    Clin Vaccine Immunol; 2014 Jun; 21(6):854-8. PubMed ID: 24717970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IgM specific to lipopolysaccharide of Vibrio cholerae is a surrogate antibody isotype responsible for serum vibriocidal activity.
    Yang JS; An SJ; Jang MS; Song M; Han SH
    PLoS One; 2019; 14(3):e0213507. PubMed ID: 30845262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of immunoglobulin M memory to both a T-cell-independent and a T-cell-dependent antigen following infection with Vibrio cholerae O1 in Bangladesh.
    Kendall EA; Tarique AA; Hossain A; Alam MM; Arifuzzaman M; Akhtar N; Chowdhury F; Khan AI; Larocque RC; Harris JB; Ryan ET; Qadri F; Calderwood SB
    Infect Immun; 2010 Jan; 78(1):253-9. PubMed ID: 19858296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune responses to O-specific polysaccharide and lipopolysaccharide of Vibrio cholerae O1 Ogawa in adult Bangladeshi recipients of an oral killed cholera vaccine and comparison to responses in patients with cholera.
    Uddin T; Aktar A; Xu P; Johnson RA; Rahman MA; Leung DT; Afrin S; Akter A; Alam MM; Rahman A; Chowdhury F; Khan AI; Bhuiyan TR; Bufano MK; Rashu R; Yu Y; Wu-Freeman Y; Harris JB; LaRocque RC; Charles RC; Kováč P; Calderwood SB; Ryan ET; Qadri F
    Am J Trop Med Hyg; 2014 May; 90(5):873-81. PubMed ID: 24686738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholera toxin modulates the systemic immune responses against Vibrio cholerae surface antigens after repeated inoculations.
    Fernandez-Miyakawa ME; Brero ML; Mateo NA
    Microbiol Immunol; 2006; 50(8):607-19. PubMed ID: 16924145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia.
    Concha A; Giraldo A; Castañeda E; Martínez M; de la Hoz F; Rivas F; Depetris A; Svennerholm AM; Sack DA
    Bull Pan Am Health Organ; 1995 Dec; 29(4):312-21. PubMed ID: 8605522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-O-specific polysaccharide (OSP) immune responses following vaccination with oral cholera vaccine CVD 103-HgR correlate with protection against cholera after infection with wild-type Vibrio cholerae O1 El Tor Inaba in North American volunteers.
    Islam K; Hossain M; Kelly M; Mayo Smith LM; Charles RC; Bhuiyan TR; Kováč P; Xu P; LaRocque RC; Calderwood SB; Simon JK; Chen WH; Haney D; Lock M; Lyon CE; Kirkpatrick BD; Cohen M; Levine MM; Gurwith M; Harris JB; Qadri F; Ryan ET
    PLoS Negl Trop Dis; 2018 Apr; 12(4):e0006376. PubMed ID: 29624592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of anticoagulants and Ficoll on human serum antibody reactivities and functions against Mycobacterium tuberculosis.
    Gadsden NJ; Liu Y; Gati S; Chen T; Jenny-Avital ER; Achkar JM
    Tuberculosis (Edinb); 2020 Jan; 120():101901. PubMed ID: 32090862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antigen-specific memory B-cell responses in Bangladeshi adults after one- or two-dose oral killed cholera vaccination and comparison with responses in patients with naturally acquired cholera.
    Alam MM; Riyadh MA; Fatema K; Rahman MA; Akhtar N; Ahmed T; Chowdhury MI; Chowdhury F; Calderwood SB; Harris JB; Ryan ET; Qadri F
    Clin Vaccine Immunol; 2011 May; 18(5):844-50. PubMed ID: 21346055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of immune responses to the O-specific polysaccharide and lipopolysaccharide of Vibrio cholerae O1 in Bangladeshi adult patients with cholera.
    Johnson RA; Uddin T; Aktar A; Mohasin M; Alam MM; Chowdhury F; Harris JB; LaRocque RC; Bufano MK; Yu Y; Wu-Freeman Y; Leung DT; Sarracino D; Krastins B; Charles RC; Xu P; Kovác P; Calderwood SB; Qadri F; Ryan ET
    Clin Vaccine Immunol; 2012 Nov; 19(11):1712-21. PubMed ID: 22993410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 1 evaluation of Vibrio cholerae O1, serotype Inaba, polysaccharide-cholera toxin conjugates in adult volunteers.
    Gupta RK; Taylor DN; Bryla DA; Robbins JB; Szu SC
    Infect Immun; 1998 Jul; 66(7):3095-9. PubMed ID: 9632571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune responses to the O-specific polysaccharide antigen in children who received a killed oral cholera vaccine compared to responses following natural cholera infection in Bangladesh.
    Leung DT; Uddin T; Xu P; Aktar A; Johnson RA; Rahman MA; Alam MM; Bufano MK; Eckhoff G; Wu-Freeman Y; Yu Y; Sultana T; Khanam F; Saha A; Chowdhury F; Khan AI; Charles RC; Larocque RC; Harris JB; Calderwood SB; Kovác P; Qadri F; Ryan ET
    Clin Vaccine Immunol; 2013 Jun; 20(6):780-8. PubMed ID: 23515016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, immunogenicity, and lot stability of the whole cell/recombinant B subunit (WC/rCTB) cholera vaccine in Peruvian adults and children.
    Taylor DN; Cárdenas V; Perez J; Puga R; Svennerholm AM
    Am J Trop Med Hyg; 1999 Dec; 61(6):869-73. PubMed ID: 10674661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Memory B cell and other immune responses in children receiving two doses of an oral killed cholera vaccine compared to responses following natural cholera infection in Bangladesh.
    Leung DT; Rahman MA; Mohasin M; Patel SM; Aktar A; Khanam F; Uddin T; Riyadh MA; Saha A; Alam MM; Chowdhury F; Khan AI; Charles R; LaRocque R; Harris JB; Calderwood SB; Qadri F; Ryan ET
    Clin Vaccine Immunol; 2012 May; 19(5):690-8. PubMed ID: 22441386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipopolysaccharide-specific memory B cell responses to an attenuated live cholera vaccine are associated with protection against Vibrio cholerae infection.
    Haney DJ; Lock MD; Gurwith M; Simon JK; Ishioka G; Cohen MB; Kirkpatrick BD; Lyon CE; Chen WH; Sztein MB; Levine MM; Harris JB
    Vaccine; 2018 May; 36(20):2768-2773. PubMed ID: 29655627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibacterial and antitoxin responses in the serum and milk of cholera patients.
    Majumdar AS; Dutta P; Dutta D; Ghose AC
    Infect Immun; 1981 Apr; 32(1):1-8. PubMed ID: 7216479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vibrio cholerae Sialidase-Specific Immune Responses Are Associated with Protection against Cholera.
    Kaisar MH; Bhuiyan MS; Akter A; Saleem D; Iyer AS; Dash P; Hakim A; Chowdhury F; Khan AI; Calderwood SB; Harris JB; Ryan ET; Qadri F; Charles RC; Bhuiyan TR
    mSphere; 2021 Apr; 6(2):. PubMed ID: 33910997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Saliva, breast milk, and serum antibody responses as indirect measures of intestinal immunity after oral cholera vaccination or natural disease.
    Jertborn M; Svennerholm AM; Holmgren J
    J Clin Microbiol; 1986 Aug; 24(2):203-9. PubMed ID: 3528211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of immune responses in patients infected with Vibrio cholerae O139 and O1.
    Qadri F; Wennerås C; Albert MJ; Hossain J; Mannoor K; Begum YA; Mohi G; Salam MA; Sack RB; Svennerholm AM
    Infect Immun; 1997 Sep; 65(9):3571-6. PubMed ID: 9284121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experimental studies on cholera immunization. 4. The antibody response to formalinized Vibrio cholerae and purified endotoxin with special reference to protective capacity.
    Svennerholm AM
    Int Arch Allergy Appl Immunol; 1975; 49(4):434-52. PubMed ID: 808500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.